Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy

BMC Cancer

Research Article

Suk-Joon Chang¹  Tae Wook Kong¹  Hee-Sug Ryu¹  Young-Taek Oh²  Mison Chun²  Sang-Won Kim³  Seung Hee Kang⁴ 

[1] Department of Obstetrics and Gynecology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, 16499, Suwon, Gyeonggi-do, Republic of Korea;Department of Radiation Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, 16499, Suwon, Gyeonggi-do, Republic of Korea;Department of Radiation Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, 16499, Suwon, Gyeonggi-do, Republic of Korea;Department of Radiation Oncology, Konyang University College of Medicine, 158 Gwanjeodong-ro, Seo-gu, 35365, Daejeon, Republic of Korea;Department of Radiation Oncology, Ilsan Paik Hospital, Inje University School of Medicine, 170 Juhwa-ro, Ilsanseo-gu, 10380, Goyang, Gyeonggi-do, Republic of Korea;

关键词: Uterine cervical neoplasm;    Adjuvant chemoradiotherapy;    Time to treatment;    Treatment outcome;    Long term adverse effects;   

DOI  :  10.1186/s12885-017-3299-0

 received in 2017-01-17, accepted in 2017-04-25,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe aim of the present study was to investigate the long-term survival outcomes and toxicities associated with our experienced early administration of adjuvant concurrent chemoradiotherapy (CCRT).MethodsNinety-eight patients with pelvic lymph node metastasis, positive resection margin, and/or parametrial invasion who received adjuvant CCRT between 1995 and 2011 were analyzed retrospectively. The first cycle of platinum-based adjuvant chemotherapy was initiated within 2–3 weeks after surgery (median, 12 days) and continued every 4 weeks for a total of 4 cycles. Adjuvant radiotherapy was performed during the second and third cycles of chemotherapy.ResultsAfter a median follow-up period of 119 months for survivors, 13 patients (13.3%) experienced recurrence and 11 patients died of cancer during the follow-up period. The 5-year recurrence-free survival and cancer specific survival rates were 87.6% and 90.6%, respectively. Ninety-four patients (95.9%) received ≥3 cycles of chemotherapy. Total radiation dose of ≥45 Gy was delivered in 91 patients (92.9%). Grade 3–4 hematologic and gastrointestinal toxicities developed in 37 (37.8%) and 14 (14.3%) patients during CCRT, respectively.ConclusionThe present study confirmed the long-term safety and encouraging survival outcomes of early administration of adjuvant CCRT, suggesting the benefits of early time to initiation of adjuvant treatments.

【 授权许可】

CC BY   
© The Author(s). 2017